HRP20150487T1 - Kompozicije za primjenu u lijeäśenju virusnih infekcija - Google Patents
Kompozicije za primjenu u lijeäśenju virusnih infekcija Download PDFInfo
- Publication number
- HRP20150487T1 HRP20150487T1 HRP20150487TT HRP20150487T HRP20150487T1 HR P20150487 T1 HRP20150487 T1 HR P20150487T1 HR P20150487T T HRP20150487T T HR P20150487TT HR P20150487 T HRP20150487 T HR P20150487T HR P20150487 T1 HRP20150487 T1 HR P20150487T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- influenza
- compound
- group
- use according
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title claims 7
- 230000009385 viral infection Effects 0.000 title claims 7
- 239000000203 mixture Substances 0.000 title 1
- 241000700605 Viruses Species 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 13
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 7
- 241000709661 Enterovirus Species 0.000 claims 7
- 241000712431 Influenza A virus Species 0.000 claims 7
- 241000713196 Influenza B virus Species 0.000 claims 7
- 241000315672 SARS coronavirus Species 0.000 claims 7
- 108020000999 Viral RNA Proteins 0.000 claims 7
- 241000710772 Yellow fever virus Species 0.000 claims 7
- 229940051021 yellow-fever virus Drugs 0.000 claims 7
- 241000725619 Dengue virus Species 0.000 claims 5
- 241000712890 Junin mammarenavirus Species 0.000 claims 5
- 241000712079 Measles morbillivirus Species 0.000 claims 5
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 5
- 241000725643 Respiratory syncytial virus Species 0.000 claims 5
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 5
- 241000710886 West Nile virus Species 0.000 claims 5
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 230000003612 virological effect Effects 0.000 claims 5
- 241001115402 Ebolavirus Species 0.000 claims 4
- 241001115401 Marburgvirus Species 0.000 claims 4
- 241000712892 Arenaviridae Species 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 claims 3
- 241000711950 Filoviridae Species 0.000 claims 3
- 241000710781 Flaviviridae Species 0.000 claims 3
- 241000711504 Paramyxoviridae Species 0.000 claims 3
- 241000150350 Peribunyaviridae Species 0.000 claims 3
- 241000712910 Pichinde mammarenavirus Species 0.000 claims 3
- 241000709664 Picornaviridae Species 0.000 claims 3
- 241000713126 Punta Toro virus Species 0.000 claims 3
- 241000713124 Rift Valley fever virus Species 0.000 claims 3
- 241000710924 Togaviridae Species 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- 241001493160 California encephalitis virus Species 0.000 claims 2
- 241000709687 Coxsackievirus Species 0.000 claims 2
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 2
- 241000991587 Enterovirus C Species 0.000 claims 2
- 241000190708 Guanarito mammarenavirus Species 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims 2
- 241000713102 La Crosse virus Species 0.000 claims 2
- 241000712902 Lassa mammarenavirus Species 0.000 claims 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 2
- 241000712898 Machupo mammarenavirus Species 0.000 claims 2
- 241000150452 Orthohantavirus Species 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000000705 Rift Valley Fever Diseases 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 241000700647 Variola virus Species 0.000 claims 2
- 241000710951 Western equine encephalitis virus Species 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims 2
- 229960001084 peramivir Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 claims 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims 1
- 241000711517 Torovirus Species 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229950004244 laninamivir Drugs 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Spoj formule I:
[image]
naznačen time da A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, za primjenu u liječenju, suzbijanju ili sprečavanju virusne infekcije.
2. Spoj za primjenu prema zahtjevu 1, naznačen time da spomenuta virusna infekcija obuhvaća infekciju s jednim ili više virusa.
3. Spoj za primjenu prema bilo kojem od zahtjeva 1-2, naznačen time da virusna infekcija obuhvaċa virus izabran iz grupe koja se sastoji od orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae familija; ili
naznačen time da je virusna infekcija izabrana iz grupe koja se sastoji od adenovirusa, rinovirusa, hepatitis virusa, virusa imunodeficijencije, polio virusa, virusa morbila, Ebola virusa, koksaki virusa, rino virusa, virusa Zapadnog Nila, virusa variole, virusa encefalitisa, virusa žute groznice, virusa denga groznice, influenca A virusa, influenca B virusa, lasa virusa, virusa limfocitnog horiomeningitisa, junin virusa, mačupo virusa, gvanarito virusa, hantavirusa, virusa groznice doline Rift, La Kros virusa, virusa kalifornijskog encefalitisa, virusa krimsko-kongoanske hemoragijske groznice, Marburg virusa, japanskog encefalitisa, virusa šume Kijasanur, virusa venecuelanskog konjskog encefalitisa, virusa istočnog konjskog encefalitisa, virusa zapadnog konjskog encefalitisa, virusa teškog akutnog respiratornog sindroma (SARS), parainfluenca virusa, respiratornog sincicijalnog virusa Punta Toro virusa, Takaribe virusa i pachindae virusa; ili
naznačen time da je virusna infekcija izabrana iz grupe koja se sastoji od adenovirusa, virusa denga groznice, influenca A virusa, influenca B virusa, Junin virusa, virusa morbila, parainfluenca virusa, Pichinde virusa, punta toro virusa, respiratornog sincicijalnog virusa, rinovirusa, virusa groznice doline Rift, SARS-CoV virusa, Takaribe virusa, viruss venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i virusa žute groznice; ili
naznačen time da je virusna infekcija izabrana iz grupe koja se sastoji od Ebola virusa, virusa žute groznice, Marburg virusa, influenca A virusa i influenca B virusa.
4. Spoj formule I:
[image]
naznačen time da A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, za primjenu u inhibiciji virusne RNK polimeraze izabrane iz grupe koja se sastoji od virusnih polimeraza orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae i coronaviridae.
5. Spoj za primjenu prema zahtjevu 4, naznačen time da se inhibira druga virusna RNK polimeraza.
6. Spoj za primjenu prema zahtjevu 5, naznačen time da je druga virusna RNK polimeraza izabrana iz grupe koja se sastoji od virusnih polimeraza orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae.
7. Spoj za primjenu prema zahtjevu 5 ili 6, naznačen time da je druga virusna RNK polimeraza izabrana iz grupe koja se sastoji od virusnih polimeraza adenovirusa, influenca A virusa, influenca B virusa, parainfluenca virusa, respiratornog sincicijalnog virusa, rinovirusa, Junin virusa, Pichinde virusa, virusa groznice doline Rift, virusa denga groznice, virusa morbila, virusa žute groznice, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i SARS-CoV virusa.
8. Spoj za primjenu prema bilo kojem od zahtjeva 4-7, naznačen time da je virusna RNK polimeraza izabrana iz grupe koja se sastoji od virusnih polimeraza adenovirusa, rinovirusa, hepatitis virusa, virusa imunodeficijencije, polio virusa, virusa morbila, Ebola virusa, koksaki virusa, rino virusa, virusa Zapadnog Nila, virusa variole, virusa encefalitisa, virusa žute groznice, virusa denga groznice, influenca A virusa, influenca B virusa, lasa virusa, virusa limfocitnog horiomeningitisa, Junin virusa, mačupo virusa, gvanarito virusa, hantavirusa, virusa groznice doline Rift, La Kros virusa, virusa kalifornijskog encefalitisa, virusa krimsko-kongoanske hemoragijske groznice, Marburg virusa, japanskog encefalitisa, virusa šume Kijasanur, virusa venecuelanskog konjskog encefalitisa, virusa istočnog konjskog encefalitisa, virusa zapadnog konjskog encefalitisa, virusa teškog akutnog respiratornog sindroma (SARS), parainfluenca virusa, respiratornog sincicijalnog virusa, Punta Toro virusa, Takaribe virusa i pachindae virusa; ili
naznačen time da je virusna RNK polimeraza polimeraza izabrana iz grupe koja se sastoji od virusnih polimeraza adenovirusa, virusa denga groznice, influenca A virusa, influenca B virusa, Junin virusa, virusa morbila, parainfluenca virusa, Pichinde virusa, Punto Toro virusa, respiratornog sincicijalnog virusa, rinovirusa, virusa groznice doline Rift, SARS-CoV virusa, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i virusa žute groznice; ili
naznačen time da je virusna RNK polimeraza polimeraza izabrana iz grupe koja se sastoji od Ebola virusa, virusa žute groznice, Marburg virusa, influenca A virusa i influenca B virusa.
9. Spoj za primjenu prema bilo kojem od prethodnih zahtjeva, koji dalje obuhvaća administraciju dodatnog antivirusnog agensa.
10. Spoj za primjenu prema zahtjevu 9, naznačen time da je dodatni antivirusni agens izabran iz grupe koja se sastoji od laninamivira, oseltamivira, zanamivira, i peramivira.
11. Spoj za primjenu prema zahtjevu 9 ili 10, naznačen time da je dodatni antivirusni agens peramivir.
12. Spoj za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time da je taj spoj za intravensku, interperitonealnu, intramuskularnu, ili oralnu administraciju.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39352210P | 2010-10-15 | 2010-10-15 | |
US201161492054P | 2011-06-01 | 2011-06-01 | |
PCT/US2011/056421 WO2012051570A1 (en) | 2010-10-15 | 2011-10-14 | Methods and compositions for inhibition of polymerase |
EP11833515.7A EP2627334B1 (en) | 2010-10-15 | 2011-10-14 | Compositions for use in the treatment of viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150487T1 true HRP20150487T1 (hr) | 2015-08-28 |
Family
ID=45938737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150487TT HRP20150487T1 (hr) | 2010-10-15 | 2015-05-06 | Kompozicije za primjenu u lijeäśenju virusnih infekcija |
HRP20180220TT HRP20180220T1 (hr) | 2010-10-15 | 2018-02-06 | Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180220TT HRP20180220T1 (hr) | 2010-10-15 | 2018-02-06 | Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija |
Country Status (24)
Country | Link |
---|---|
US (6) | US20130331404A1 (hr) |
EP (3) | EP2627334B1 (hr) |
JP (2) | JP5902698B2 (hr) |
KR (1) | KR101850925B1 (hr) |
CN (1) | CN103429245B (hr) |
AU (2) | AU2011315902B2 (hr) |
BR (1) | BR112013009029B1 (hr) |
CA (1) | CA2813783C (hr) |
CY (1) | CY1119880T1 (hr) |
DK (2) | DK2898885T3 (hr) |
ES (2) | ES2536831T3 (hr) |
HK (2) | HK1212914A1 (hr) |
HR (2) | HRP20150487T1 (hr) |
HU (1) | HUE036387T2 (hr) |
IL (1) | IL225672B (hr) |
LT (1) | LT2898885T (hr) |
MX (1) | MX348759B (hr) |
PL (2) | PL2627334T3 (hr) |
PT (2) | PT2627334E (hr) |
RS (2) | RS56870B1 (hr) |
RU (3) | RU2599013C2 (hr) |
SI (2) | SI2627334T1 (hr) |
SM (1) | SMT201500148B (hr) |
WO (1) | WO2012051570A1 (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2280973E (pt) | 2008-04-23 | 2013-02-04 | Gilead Sciences Inc | Análogos de carba-nucleósido para tratamento antiviral |
CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
BR112013001267A2 (pt) | 2010-07-19 | 2016-05-17 | Gilead Sciences Inc | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro |
SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
ES2536831T3 (es) | 2010-10-15 | 2015-05-29 | Biocryst Pharmaceuticals, Inc. | Métodos y composiciones para inhibición de polimerasa |
AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
EP2919785A4 (en) * | 2012-11-16 | 2016-10-05 | Biocryst Pharm Inc | ANTIVIRAL NUCLEOSIDES CONTAINING AZASUCRE |
EP2996685B1 (en) * | 2013-05-14 | 2019-03-27 | Biocryst Pharmaceuticals, Inc. | Anti-influenza compositions and methods |
TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
CN104513249B (zh) * | 2014-12-26 | 2016-08-31 | 苏州明锐医药科技有限公司 | 抗埃博拉病毒药物bcx4430的制备方法 |
LT3785717T (lt) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | Coronaviridae infekcijų gydymo būdai |
MA43812A (fr) * | 2016-03-06 | 2018-11-28 | Biocryst Pharm Inc | Procédés et compositions pour le traitement d'une infection par le virus zika |
DE102016002873A1 (de) | 2016-03-09 | 2016-05-25 | Heinz Kiefer | Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind |
US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
WO2021007283A1 (en) * | 2019-07-09 | 2021-01-14 | Regents Of The University Of Minnesota | Potentiation of antiviral nucleobases as rna virus therapy |
TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
AU2021234308C1 (en) | 2020-03-12 | 2024-02-22 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
WO2021207386A1 (en) * | 2020-04-07 | 2021-10-14 | Biocryst Pharmaceuticals, Inc. | Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections |
TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
TW202233204A (zh) | 2020-08-27 | 2022-09-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
EP4360629A1 (en) * | 2021-06-25 | 2024-05-01 | Industry Foundation of Chonnam National University | Pharmaceutical composition comprising lipase inhibitor for treatment or treatment of rna viral infections |
WO2023023469A1 (en) * | 2021-08-17 | 2023-02-23 | Southwest Research Institute | Inhibitors for coronavirus |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9520364D0 (en) * | 1995-10-05 | 1995-12-06 | Chiroscience Ltd | Compouundds |
US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
US6228741B1 (en) | 1998-01-13 | 2001-05-08 | Texas Instruments Incorporated | Method for trench isolation of semiconductor devices |
US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
WO2003100009A2 (en) * | 2002-05-23 | 2003-12-04 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
US7560434B2 (en) * | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
US7514410B2 (en) * | 2005-03-29 | 2009-04-07 | Biocryst Pharmaceuticals, Inc. | Hepatitis C therapies |
US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
AU2007293774C1 (en) | 2006-09-07 | 2014-12-18 | Albert Einstein College Of Medicine, Inc. | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
WO2008067002A2 (en) | 2006-09-11 | 2008-06-05 | Southern Research Institute | Azole nucleosides and use as inhibitors of rna and dna varial polymerases |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
ES2536831T3 (es) | 2010-10-15 | 2015-05-29 | Biocryst Pharmaceuticals, Inc. | Métodos y composiciones para inhibición de polimerasa |
EP2638007A2 (en) | 2010-11-11 | 2013-09-18 | Redx Pharma Limited | Drug derivatives |
AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
-
2011
- 2011-10-14 ES ES11833515.7T patent/ES2536831T3/es active Active
- 2011-10-14 EP EP11833515.7A patent/EP2627334B1/en active Active
- 2011-10-14 EP EP17196354.9A patent/EP3345605B1/en active Active
- 2011-10-14 JP JP2013534046A patent/JP5902698B2/ja active Active
- 2011-10-14 PL PL11833515T patent/PL2627334T3/pl unknown
- 2011-10-14 CA CA2813783A patent/CA2813783C/en active Active
- 2011-10-14 RS RS20180135A patent/RS56870B1/sr unknown
- 2011-10-14 WO PCT/US2011/056421 patent/WO2012051570A1/en active Application Filing
- 2011-10-14 RU RU2013121794/15A patent/RU2599013C2/ru active
- 2011-10-14 BR BR112013009029-4A patent/BR112013009029B1/pt active IP Right Grant
- 2011-10-14 DK DK14198125.8T patent/DK2898885T3/en active
- 2011-10-14 DK DK11833515.7T patent/DK2627334T3/en active
- 2011-10-14 CN CN201180059786.9A patent/CN103429245B/zh active Active
- 2011-10-14 HU HUE14198125A patent/HUE036387T2/hu unknown
- 2011-10-14 PT PT118335157T patent/PT2627334E/pt unknown
- 2011-10-14 US US13/879,110 patent/US20130331404A1/en not_active Abandoned
- 2011-10-14 SI SI201130489T patent/SI2627334T1/sl unknown
- 2011-10-14 LT LTEP14198125.8T patent/LT2898885T/lt unknown
- 2011-10-14 MX MX2013003938A patent/MX348759B/es active IP Right Grant
- 2011-10-14 EP EP14198125.8A patent/EP2898885B1/en active Active
- 2011-10-14 AU AU2011315902A patent/AU2011315902B2/en active Active
- 2011-10-14 ES ES14198125.8T patent/ES2657687T3/es active Active
- 2011-10-14 PL PL14198125T patent/PL2898885T3/pl unknown
- 2011-10-14 PT PT141981258T patent/PT2898885T/pt unknown
- 2011-10-14 KR KR1020137012318A patent/KR101850925B1/ko active IP Right Grant
- 2011-10-14 RU RU2016134401A patent/RU2718690C2/ru active
- 2011-10-14 SI SI201131383T patent/SI2898885T1/en unknown
- 2011-10-14 RS RS20150369A patent/RS54072B1/en unknown
-
2013
- 2013-04-10 IL IL225672A patent/IL225672B/en active IP Right Grant
-
2014
- 2014-11-03 US US14/531,471 patent/US9492452B2/en active Active
-
2015
- 2015-05-06 HR HRP20150487TT patent/HRP20150487T1/hr unknown
- 2015-06-25 SM SM201500148T patent/SMT201500148B/xx unknown
-
2016
- 2016-01-28 HK HK16100950.0A patent/HK1212914A1/zh unknown
- 2016-03-10 JP JP2016046875A patent/JP2016135790A/ja not_active Withdrawn
- 2016-10-28 US US15/337,320 patent/US10022375B2/en active Active
-
2017
- 2017-01-24 AU AU2017200471A patent/AU2017200471B2/en active Active
-
2018
- 2018-02-02 CY CY20181100131T patent/CY1119880T1/el unknown
- 2018-02-06 HR HRP20180220TT patent/HRP20180220T1/hr unknown
- 2018-06-20 US US16/013,059 patent/US10420769B2/en active Active
- 2018-12-25 HK HK18116571.3A patent/HK1257363A1/zh unknown
-
2019
- 2019-08-16 US US16/543,079 patent/US11173159B2/en active Active
-
2020
- 2020-03-17 RU RU2020111042A patent/RU2020111042A/ru unknown
-
2021
- 2021-10-21 US US17/506,836 patent/US20220040190A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150487T1 (hr) | Kompozicije za primjenu u lijeäśenju virusnih infekcija | |
JP2013544788A5 (hr) | ||
JP2016504284A5 (hr) | ||
NZ596014A (en) | Dihydroorotate - dehydrogenase inhibitors as virostatic compounds | |
RU2020116571A (ru) | N4-гидроксицитидин и производные и связанные с этим противовирусные применения | |
HRP20171036T1 (hr) | Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c | |
JP2015514772A5 (hr) | ||
JP2009517395A5 (hr) | ||
WO2007103111A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
DE602006015861D1 (de) | Antivirale verbindungen | |
NO20091258L (no) | Entantiomerisk rene fosfoindoler as HIV inhibitorer | |
WO2007100888A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
ATE541844T1 (de) | Antivirale verbindungen | |
WO2008147474A8 (en) | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | |
BR112012008533A8 (pt) | combinações de inibidores do vírus da hepatite c | |
JP2014530874A5 (hr) | ||
EA201201235A1 (ru) | Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv | |
NZ597544A (en) | Modified 4'-nucleosides as antiviral agents | |
EA200701669A1 (ru) | Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae | |
NZ610715A (en) | Antiviral compounds and methods | |
HRP20200045T1 (hr) | Metode sa oligonukleotidnim helatnim kompleksom | |
WO2010036399A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
PE20090228A1 (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
MX2009012299A (es) | Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue. |